Opening: Test report scenario
▎Clinical Scenario — A PGT‑A test report shows: out of 5 blastocysts, only 1 is chromosomally normal (46,XY), while the remaining 4 exhibit trisomy 21, trisomy 16, 45X, and 47,XXY respectively. The patient is 38 years old, with AMH 1.1 ng/mL, and a history of 2 spontaneous miscarriages.
What is a chromosomal abnormality? How to address it in overseas IVF
A chromosomal abnormality refers to a change in the number or structure of chromosomes in embryonic cells, including aneuploidy (e.g., trisomy 21, trisomy 16, 45X), structural abnormalities (balanced translocation, Robertsonian translocation, inversion), and mosaicism (coexistence of normal and abnormal cells). In the overseas IVF process, PGT‑A (Preimplantation Genetic Testing for Aneuploidy) is the primary tool for identifying these issues.
Clinical decision pathway: After PGT‑A screening, the transfer strategy is determined based on embryonic chromosomal results, morphological grading, patient age, and previous pregnancy history. For patients with recurrent implantation failure or recurrent miscarriage, peripheral blood karyotype analysis of both partners is recommended to rule out occult balanced translocation carriers.
Mechanisms of chromosomal abnormalities
Embryonic chromosomal abnormalities mainly originate from meiotic errors in oocytes, with a minority arising from errors during spermatogenesis or early embryonic mitotic errors. Female age is a core variable affecting meiotic accuracy: as age increases, the function of the spindle assembly checkpoint in oocytes declines, significantly raising the risk of chromosome non-disjunction.
- Meiotic errors: Account for over 80% of aneuploidy sources, more common in advanced maternal age women.
- Mitotic errors: Occur during early embryonic cleavage stages, leading to mosaicism or confined abnormalities.
- Parental structural abnormalities: For example, balanced translocation carriers produce unbalanced gametes during meiosis.
Additionally, paternal factors (high sperm DNA fragmentation, chromosomal structural rearrangements) and environmental factors (radiation, chemical exposure) also contribute, but their impact is far less significant than female age.
Age stratification: Clinical data on chromosomal abnormality rates
The following data are based on PGT‑A screening results from overseas IVF patients at our center over the past three years (n=1,247 cycles), stratified by female age:
| Female Age | Cycles | Embryo Normal Rate | Aneuploidy Rate | Mosaicism Rate |
|---|---|---|---|---|
| ≤34 years | 412 | 62.3% | 28.1% | 9.6% |
| 35-37 years | 358 | 51.8% | 37.2% | 11.0% |
| 38-40 years | 296 | 34.5% | 52.6% | 12.9% |
| 41-42 years | 124 | 20.3% | 67.8% | 11.9% |
| ≥43 years | 57 | 8.9% | 79.2% | 11.9% |
It can be observed that after age 38, the normal embryo rate significantly declines, and above age 43, the normal rate falls below 10%. AMH levels correlate with follicle count but do not directly improve the chromosomal abnormality rate.
Typical case analysis
Case 1 · 38 years old, AMH 1.1, bilateral antral follicle count 7, history of 2 spontaneous miscarriages.
10 eggs retrieved, 8 mature, 6 fertilized, 5 blastocysts formed and sent for PGT‑A. Results: 1 normal (46,XY), 1 trisomy 21, 1 trisomy 16, 1 45X, 1 mosaic (20% 47,XXY).
Decision: Prioritize transfer of the normal embryo; the mosaic embryo is considered as a backup after genetic counseling; recommend another egg retrieval to accumulate embryos.
Case 2 · 42 years old, AMH 0.6, bilateral antral follicle count 4, history of 1 failed IVF cycle.
5 eggs retrieved, 4 mature, 3 fertilized, 2 blastocysts formed. PGT‑A results: 1 trisomy 22, 1 45X. No transferable normal embryo.
Decision: After discussion with the patient, choose another egg retrieval while evaluating egg donation as a backup option.
Case 3 · 35 years old, recurrent miscarriage 3 times, karyotype analysis of both partners reveals the female is a balanced translocation carrier: 46,XX,t(7;11)(q22;q23).
14 eggs retrieved, 8 blastocysts formed, after PGT‑SR (structural rearrangement testing) 2 normal/balanced embryos obtained. 1 embryo transferred, singleton pregnancy progressing smoothly.
Key point: For patients with recurrent miscarriage and younger age, couple karyotype analysis should be completed before PGT.
Easily overlooked details
- Mosaicism ratio and transfer potential: When the mosaicism ratio is <30%, some embryos can still be transferred and result in healthy live births, but this requires genetic counseling and prenatal diagnosis.
- Uniparental disomy (UPD): Cannot be detected by routine PGT‑A platforms; requires SNP‑array or methylation testing for identification. UPD can lead to imprinting disorders.
- Mitochondrial DNA abnormalities: Unrelated to chromosomal abnormalities but affect embryonic developmental potential; not covered by routine PGT‑A.
- Sperm DNA fragmentation index (DFI): When DFI >30%, even with normal embryonic chromosomes, the risk of implantation failure and miscarriage increases.
- Differences in interpretation across testing platforms: NGS and aCGH platforms have different sensitivities and thresholds for mosaicism; overseas clinics should confirm the testing platform standards.
Frequently asked questions from patients
Q: Can miscarriage still occur after transferring a PGT‑A normal embryo?
A: Yes. PGT‑A only screens for chromosomal number and large segment structural abnormalities; it cannot rule out miscarriages caused by single gene disorders, imprinting defects, UPD, or maternal factors. The miscarriage rate after normal embryo transfer is about 5-10%, lower than the unscreened group.
Q: Can I still undergo overseas IVF with PGT‑A if my AMH is low?
A: Low AMH does not necessarily mean a higher rate of chromosomal abnormalities in eggs, but fewer eggs retrieved may result in no blastocysts available for testing. It is recommended to comprehensively evaluate based on age, AMH, and previous pregnancy history, and consider multiple egg retrievals to accumulate embryos if necessary.
Q: If the male partner's chromosomes are normal, is sperm DFI testing still necessary?
A: It is recommended. Normal karyotype does not rule out sperm DNA damage; elevated DFI is associated with embryonic developmental arrest, implantation failure, and miscarriage, especially in advanced paternal age or with factors like smoking and varicocele.
Q: How far in advance should I prepare my passport and documents for overseas IVF?
A: Passport validity should be at least 6 months, and some countries require 12 months. Marriage certificate, birth certificate notarization, translations, etc., should be prepared 2-3 months in advance, subject to the requirements of the destination country.
Practitioner observations
In clinical practice, we have identified three types of situations most commonly underestimated in overseas IVF chromosomal abnormality cases:
- Occult balanced translocation — Patients are younger with recurrent miscarriage, but routine karyotype analysis is normal. In such cases, chromosomal microarray analysis (CMA) or whole genome sequencing is recommended to potentially identify hidden rearrangements.
- Clinical significance of low-level mosaicism — Some laboratories directly classify mosaic embryos as "abnormal" and discard them, but low-level mosaic embryos (<20%) have live birth rates close to normal embryos and should not be excessively discarded.
- Differences in PGT‑A laws and ethics across countries — For example, the permissibility of transferring mosaic embryos varies in the US, Thailand, Japan, etc., affecting patients' transfer strategy choices.
Additionally, in overseas IVF, embryo transport and time zone communication are also prone to issues. It is recommended that patients confirm with the laboratory after embryo biopsy regarding the testing platform, reporting cycle, and mosaicism threshold to avoid decision delays due to information asymmetry.
▎Risk Reminder
PGT‑A screening cannot 100% rule out chromosomal abnormalities; there is a possibility of false negatives (approximately 1-2%) and false positives (approximately 2-5%). Prenatal diagnosis (amniocentesis) is required after transferring mosaic embryos. For patients of advanced age, with diminished ovarian reserve, or with repeated failure, the risk of "no transferable embryo" should be fully understood, and alternative plans should be made under medical guidance. All overseas IVF decisions must be made in accordance with the laws and regulations of the respective country and the patient's individual circumstances, jointly determined by the reproductive medicine team, genetic counselor, and patient.
Comments (0)